18F-AzaFol的辐射剂量学:叶酸受体PET示踪剂首次人体应用
在前瞻性多中心试验(NCT03242993)中,6例经组织学确诊的肺腺癌患者接受18F-AzaFol(327 MBq,范围299-399 MBq)静脉注射,于注射后3至60分钟行TOF-PET显像以建立剂量学。未观察到严重相关不良事件,最高器官吸收剂量位于肝脏、肾脏、膀胱和脾脏,患者有效剂量超过临床前数据外推值,作者认为该示踪剂剂量学性质良好、值得进一步评估。
要点
- 6例肺腺癌患者中未观察到严重相关不良事件。
- 肝脏、肾脏、膀胱和脾脏吸收剂量最高,分别为51.9、45.8、39.1和35.4 μGy/MBq。
- 患者有效剂量超过临床前数据外推值14.0 μSv/MBq。
核心结论
- 18F-AzaFol是一种剂量学性质良好的PET示踪剂,患者辐射剂量负担合理,值得进一步评估其表现。
研究设计与样本
- 前瞻性多中心试验(NCT03242993)纳入6例经组织学确诊、有可测量病灶(按RECIST 1.1≥10 mm)的肺腺癌患者。
- 静脉注射327 MBq(范围299-399 MBq)18F-AzaFol后,于3、11、18、30、40、50和60分钟行TOF-PET显像以建立剂量学。
- 使用OLINDA/EXM v.2.0软件评估器官吸收剂量、肿瘤吸收剂量和患者有效剂量,并与临床前结果比较。
主要发现
- 未观察到严重相关不良事件。
- 最高器官吸收剂量位于肝脏、肾脏、膀胱和脾脏,分别为51.9、45.8、39.1和35.4 μGy/MBq。
- 估计患者和性别平均有效剂量分别为18.0±2.6和19.7±1.4 μSv/MBq。
- 人体有效剂量超过从临床前数据外推的14.0 μSv/MBq。
- 平均肿瘤吸收剂量为34.8 μGy/MBq(范围13.6-60.5 μGy/MBq)。
局限性
- 作者在结论中表示该示踪剂值得进一步评估以评估其表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the 18F-AzaFol (3'-aza-2'-[18F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα. MATERIAL AND METHODS: Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with measurable lesions (≥ 10 mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60 min after the intravenous injection of 327 MBq (range 299-399 MBq) of 18F-AzaFol to establish dosimetry. Organ absorbed doses (AD), tumor AD, and patient effective doses (E) were assessed using the OLINDA/EXM v.2.0 software and compared with pre-clinical results. RESULTS: No serious related adverse events were observed. The highest AD were in the liver, the kidneys, the urinary bladder, and the spleen (51.9, 45.8, 39.1, and 35.4 μGy/MBq, respectively). Estimated patient and gender-averaged E were 18.0 ± 2.6 and 19.7 ± 1.4 μSv/MBq, respectively. E in-human exceeded the value of 14.0 μSv/MBq extrapolated from pre-clinical data. Average tumor AD was 34.8 μGy/MBq (range 13.6-60.5 μGy/MBq). CONCLUSIONS: 18F-Azafol is a PET agent with favorable dosimetric properties and a reasonable radiation dose burden for patients which merits further evaluation to assess its performance. TRIAL REGISTRATION: ClinicalTrial.gov, NCT03242993, posted on August 8, 2017.
引用
- Gnesin S, Müller J, Burger IA, et al. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res. 2020. PMID: 32270313. doi:10.1186/s13550-020-00624-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。